Paper Details

  1. Home
  2. Paper Details

Apremilast and its role in psoriatic arthritis.

Author: EderLihi, SandhuVijay K, YeungJensen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin. Apremilast is a new oral medication that has been approved for the treatment of PsA. Apremilast works by inhibiting phosphodiesterase-4, an enzyme that is involved in the production of proinflammatory mediators. Clinical trials have shown that apremilast is effective in improving symptoms of PsA in both patients who have not previously been treated with disease-modifying anti-rheumatic drugs (DMARDs) and those who have. However, apremilast is less effective in patients who have previously failed treatment with biologic DMARDs. The most common side effects of apremilast are gastrointestinal problems. Apremilast is generally well tolerated and may be a useful treatment option for patients with PsA who have not responded to other medications.
Paper Details　
Original Abstract of the Article :
Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis often observed in patients with skin psoriasis. Treatment of PsA, especially peripheral PsA, has typically relied on disease-modifying anti-rheumatic agents (DMARDs); however, these agents have limited efficacy and considerable assoc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.23736/S0392-0488.20.06640-7

データ提供：米国国立医学図書館（NLM）

Apremilast: A New Oasis in the Desert of Psoriatic Arthritis

Psoriatic arthritis (PsA), a disease that can feel like a relentless sandstorm of pain and inflammation, has traditionally been challenging to treat. This study examines the role of apremilast, a novel oral disease-modifying antirheumatic drug (DMARD), in managing this condition. Apremilast, like a powerful camel capable of carrying a heavy load, targets specific pathways involved in inflammation. The study, drawing upon data from phase III randomized controlled trials, reveals that apremilast can effectively improve various clinical and patient-reported outcomes for PsA. This finding is like discovering a hidden oasis in the vast desert of PsA research, offering hope for a more manageable journey.

A Promising New Treatment Option

The study's findings suggest that apremilast, like a well-trained camel navigating a difficult terrain, can effectively alleviate the symptoms of PsA. The drug's ability to improve clinical and patient-reported outcomes is like finding a source of fresh water in a desolate desert, offering relief and a chance for a better life. However, it is important to note that apremilast's effectiveness may be limited in certain patients, like encountering a dry riverbed in the desert. Further research is needed to optimize the use of apremilast and to determine its place within the broader spectrum of PsA treatments.

Navigating the Desert of Psoriatic Arthritis

This study is a significant step forward in the fight against PsA, offering a new weapon in our arsenal to combat this chronic inflammatory condition. The desert of PsA research is vast and complex, but with continued exploration and innovation, we can find new oases of knowledge and effective treatments. The study's findings provide valuable insights into the potential of apremilast and encourage us to continue searching for solutions that will alleviate the suffering of those affected by PsA.

Dr. Camel's Conclusion

This study, like a shimmering oasis in a desert of pain, offers hope for those battling Psoriatic Arthritis. Apremilast, with its promising effects, represents a significant advance in PsA treatment. The study's findings encourage us to continue exploring new avenues of research, seeking even more effective and compassionate solutions for those living with this challenging condition.
Date :
  1. Date Completed 2021-09-10
  2. Date Revised 2021-09-10
Further Info :

Pubmed ID

33050680

DOI: Digital Object Identifier

10.23736/S0392-0488.20.06640-7

Related Literature

Article Analysis
・Side Effects of apremilast
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.